Equity Profile

AXSM

AXSOME THERAPEUTICS

Health CarePharmaceuticals$12.0B

May4Mon

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Axsome Therapeutics Misses on EPS, Stock Up 8.31%

Metric	Actual	Expected	Surprise
EPS	$-1.26	$-0.76	-48.06%
Revenue	—	$192M	—

management commentary, guidance changes, and full analysis available with Pro.

Axsome Therapeutics Misses on EPS, Stock Up 8.31%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.26	$-0.76	-48.06%
Revenue	—	$192M	—

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

What It Means

Axsome Therapeutics reported a larger-than-expected loss per share, which disappointed analysts. Despite this, the stock rose by 8.31%, indicating that investors may be optimistic about future developments or other aspects of the business not reflected in the earnings numbers.

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

-$0.76

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$192M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $11 billion, its work is crucial as it targets unmet medical needs in mental health and neurological conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q4-2025, Axsome reported an EPS of -$0.56, which was better than analysts' expectations of -$0.70, resulting in a positive surprise. However, the stock fell 4.88% the next day, indicating market disappointment despite the beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Axsome to report a loss of $0.76 per share on revenues of $192 million. The market is closely watching how the company manages its costs and sales growth.

Bull Case

If Axsome can exceed revenue expectations and improve its EPS, it may signal strong demand for its products and effective cost management, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a wider loss, it could raise concerns about its growth prospects and operational efficiency.

Key Metrics to Watch

EPS

-$0.76

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$192M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Axsome's revenue exceed the consensus estimate of $192 million?

Revenue performance is critical for assessing market demand and the company's growth trajectory.

What specific strategies is Axsome implementing to improve its EPS from the expected -$0.76?

Understanding management's approach to cost control and revenue generation will be key to evaluating future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Axsome's ability to leverage its pipeline effectively, leading to stronger-than-expected revenue growth.

Supporting Evidence

The recent EPS surprise of +20.34% indicates potential for better performance than anticipated.

Options pricing suggests a significant move, indicating that traders expect volatility which could favor a positive outcome.

Key Risk

If revenue comes in below $164 million, it could undermine confidence in Axsome's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on Axsome's ability to generate revenue and improve profitability amidst ongoing operational challenges.

Bull Confirmed If

Revenue growth exceeding $192 million with a narrower EPS loss than -$0.76 would confirm the bull case.

Bear Confirmed If

A revenue figure below $164 million or an EPS loss worse than -$0.96 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.52%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility based on the results.

Options are pricing ±7.5% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

47.2%

Calls (229K)P/C Ratio: 4.66Puts (262K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests the stock could rise by about 2.93%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may experience a muted reaction as investors reassess growth prospects.

Miss

Should the company miss expectations, history suggests a potential decline of around 0.42%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on cost management strategies to improve EPS.
3Insights into market demand for Axsome's current therapies.
4Management's outlook on future growth and any potential challenges.
5Responses to questions about competitive pressures in the pharmaceutical market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

WisdomTree, Inc.

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

-$0.76

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$192M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Axsome to report a loss of $0.76 per share on revenues of $192 million. The market is closely watching how the company manages its costs and sales growth.

Bull Case

If Axsome can exceed revenue expectations and improve its EPS, it may signal strong demand for its products and effective cost management, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet revenue expectations or reports a wider loss, it could raise concerns about its growth prospects and operational efficiency.

Key Metrics to Watch

EPS

-$0.76

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$192M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Axsome's revenue exceed the consensus estimate of $192 million?

Revenue performance is critical for assessing market demand and the company's growth trajectory.

What specific strategies is Axsome implementing to improve its EPS from the expected -$0.76?

Understanding management's approach to cost control and revenue generation will be key to evaluating future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Axsome's ability to leverage its pipeline effectively, leading to stronger-than-expected revenue growth.

Supporting Evidence

The recent EPS surprise of +20.34% indicates potential for better performance than anticipated.

Options pricing suggests a significant move, indicating that traders expect volatility which could favor a positive outcome.

Key Risk

If revenue comes in below $164 million, it could undermine confidence in Axsome's growth strategy.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on Axsome's ability to generate revenue and improve profitability amidst ongoing operational challenges.

Bull Confirmed If

Revenue growth exceeding $192 million with a narrower EPS loss than -$0.76 would confirm the bull case.

Bear Confirmed If

A revenue figure below $164 million or an EPS loss worse than -$0.96 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.52%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility based on the results.

Options are pricing ±7.5% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

47.2%

Calls (229K)P/C Ratio: 4.66Puts (262K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests the stock could rise by about 2.93%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may experience a muted reaction as investors reassess growth prospects.

Miss

Should the company miss expectations, history suggests a potential decline of around 0.42%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on cost management strategies to improve EPS.
3Insights into market demand for Axsome's current therapies.
4Management's outlook on future growth and any potential challenges.
5Responses to questions about competitive pressures in the pharmaceutical market.